Nuveen Asset Management’s Mersana Therapeutics MRSN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $332K | Buy |
9,289
+3,241
| +54% | +$116K | ﹤0.01% | 3103 |
|
|
2024
Q3 | $286K | Buy |
6,048
+1,114
| +23% | +$52.6K | ﹤0.01% | 3154 |
|
|
2024
Q2 | $248K | Hold |
4,934
| – | – | ﹤0.01% | 3183 |
|
|
2024
Q1 | $553K | Buy |
4,934
+2,299
| +87% | +$257K | ﹤0.01% | 2944 |
|
|
2023
Q4 | $153K | Hold |
2,635
| – | – | ﹤0.01% | 3247 |
|
|
2023
Q3 | $83.7K | Sell |
2,635
-47,029
| -95% | -$1.49M | ﹤0.01% | 3139 |
|
|
2023
Q2 | $4.08M | Buy |
49,664
+5
| +0% | +$411 | ﹤0.01% | 2017 |
|
|
2023
Q1 | $5.1M | Buy |
49,659
+483
| +1% | +$49.6K | ﹤0.01% | 1876 |
|
|
2022
Q4 | $7.2M | Sell |
49,176
-1,589
| -3% | -$233K | ﹤0.01% | 1701 |
|
|
2022
Q3 | $8.58M | Buy |
50,765
+33,092
| +187% | +$5.59M | ﹤0.01% | 1575 |
|
|
2022
Q2 | $2.04M | Buy |
17,673
+5,695
| +48% | +$658K | ﹤0.01% | 2428 |
|
|
2022
Q1 | $1.2M | Buy |
11,978
+260
| +2% | +$26K | ﹤0.01% | 2743 |
|
|
2021
Q4 | $1.82M | Buy |
11,718
+670
| +6% | +$104K | ﹤0.01% | 2608 |
|
|
2021
Q3 | $2.6M | Buy |
11,048
+650
| +6% | +$153K | ﹤0.01% | 2547 |
|
|
2021
Q2 | $3.53M | Buy |
10,398
+701
| +7% | +$238K | ﹤0.01% | 2422 |
|
|
2021
Q1 | $3.92M | Sell |
9,697
-6,145
| -39% | -$2.49M | ﹤0.01% | 2286 |
|
|
2020
Q4 | $10.5M | Buy |
15,842
+1,075
| +7% | +$715K | ﹤0.01% | 1686 |
|
|
2020
Q3 | $6.87M | Sell |
14,767
-5,351
| -27% | -$2.49M | ﹤0.01% | 1747 |
|
|
2020
Q2 | $11.8M | Buy |
20,118
+12,387
| +160% | +$7.25M | ﹤0.01% | 1374 |
|
|
2020
Q1 | $1.13M | Buy |
7,731
+2,168
| +39% | +$316K | ﹤0.01% | 2466 |
|
|
2019
Q4 | $797K | Buy |
5,563
+1,251
| +29% | +$179K | ﹤0.01% | 2765 |
|
|
2019
Q3 | $171K | Hold |
4,312
| – | – | ﹤0.01% | 3135 |
|
|
2019
Q2 | $437K | Buy |
+4,312
| New | +$437K | ﹤0.01% | 3035 |
|